Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen Idec

Tysabri, Avonex revenues continue growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 2Q10

2Q Revenues: $1.2 billion (+11%)

2Q Earnings: $294 million (+103%)

YTD Revenues: $2.3 billion (+9%)

YTD Earnings: $515 million (+31%)

Comments: Avonex revenues grew 6% in 2Q10 and YTD to $628 million and $1.2 billion, respectively. Tysabri revenues were up 17% to $219 million in the quarter, and 24% to $438 million for the year. The company estimates that 52,700 patients worldwide are on commercial or clinical Tysabri. R&D expenses dropped 20% in 2Q10 to $332 million, and fell 8% to $639 million YTD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters